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Background: The combination of biliary stent with photodynamic and chemotherapy
seemed to be a beneficial palliative treatment of unresectable cholangiocarcinoma.
However, by intravenous delivery to the target tumor the distribution of the drug had
its limitations and caused serious side effect on non-target organs. Therefore, in this
study, we are going to develop a localized eluting stent, named PDT-chemo stent,
covered with gemcitabine (GEM) and hematoporphyrin (HP).
Methods: The prototype of PDT-chemo stent was made through electrospinning
and electrospraying dual-processes with an electrical charge to cover the stent with a
drug-storing membrane from polymer liquid. The design of prototype used PU as the
material of the backing layer, and PCL/PEG blends in different molar ratio of 9:1 and
of 1:4 were used in two drug-storing layers with GEM and HP loaded respectively.
Results: The optical microscopy revealed that the backing layer was formed in fine
fibers from electrospinning, while drug-storing layers, attributed to the droplets
from electrospraying process. The covered membrane, the morphology of which
was observed by scanning electron microscopy (SEM), covered the stent surface
homogeneously without crack appearances. The GEM had almost 100% of electrosprayed
efficiency than 70% HP loaded on the covered membrane due to the different solubility
of drug in PEG/PCL blends. Drug release study confirmed the two-phased drug release
pattern by regulating in different molar ratio of PEG/PCL blends polymer.
Conclusions: The result proves that the PDT-chemo stent is composed of a first
burst-releasing phase from HP and a later slow-releasing phase from GEM eluting.
This two-phase of drug eluting stent may provide a new prospect of localized and
controlled release treatment for cholangiocarcinoma disease.
Keywords: Cholangiocarcinoma, Photodynamic therapy, Chemotherapy, Biliary
drug-eluting stent, Electrospinning and ElectrosprayingBackground
Cholangiocarcinoma is the second most common hepatobiliary tumor, which is generally
a locally invasive tumor that occludes the biliary tree and leads to cholangitis and
liver failure. Until now, tumor resection has been the only potential cure for cholan-
giocarcinoma [1,2]. Unfortunately, even with resection, the survival rate with five
years can decrease to 11% at most and more than 50% of patients still remained at© 2014 Chen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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have obstructive cholestasis. So far, the primary standard method of treatment has
been biliary stenting [5]. However, this treatment can prolong survival time slightly by
providing temporary biliary drainage. Therefore, the secondary method of treatment
is required to prolong the survival time by reducing tumor burden. Chemotherapy
and radiotherapy are classical treatments but their results are also disappointing [3,5].
Photodynamic therapy (PDT) is a new and promising treatment option, which contains
a photosensitizer, light source, and oxygen [6]. The concept of PDT is based on a photo-
sensitizer exposed to the specific wavelength of light, which can generate cytotoxic
reactive oxygen species (ROS) to kill tumor cells [7]. Additionally, previous studies
have shown that PDT could also inhibit the P-glycoprotein efflux of drug. A combination
of PDT and chemotherapy can improve the accumulation of chemo-drug in tumor cells,
and reduce the chemo-drug resistance from the P-glycoprotein efflux [8]. Another
advantage of combination therapy with PDT and chemo-drug is the capability to induce
antitumor immunity [9]. However, by intravenous delivery to target tumor, the distribution
of the drug had its limitations and caused serious side effect on non-target organs.
After receiving PDT treatment, patients have to stay indoors, away from bright light
for 3 to 4 days to avoid the skin photosensitivity from the side effect [10].
In order to decrease the side effect during the treatment, the aim of this study is to
develop a localized drug eluting stent, named PDT-chemo stent, by incorporating
gemcitabine (GEM) with hematoporphyrin (HP) to cover the stent surface. Drug-eluting
stent has been considered a method to maximize the drug concentration immediately on
the localized tumor environment, while minimizing the non-target organs exposure
[11,12]. In clinical practice, this PDT-chemo stent could be inserted to the tumor area via
endoscopic retrograde cholangiography [13], followed by the simultaneous specific light
source from endoscopy to activate the photosensitizer for PDT. Meanwhile, the chemo-
drug of GEM will be released continuously as the second step for chemotherapy. The
multimodal function of PDT-chemo stent will not only aim to increase the accumulation
of drug within the neoplastic tissue, but also decrease the side effect on non-target tissues.
In the past decade, the stent with drug-incorporated covered membrane has been
received increasing attention as drug-eluting stent due to its functions of providing
mechanic support and releasing sufficient drug to prevent restenosis or treat malignant
[12,14,15]. Historically, several techniques were developed and have been used to
manufacture the covered membrane on stent surface. These diverse techniques include
dip coating [12,16], compression technique [14] and electrospinning [17,18]. Concerned
about the adherence and flexibility problems of the membrane covering the stent [19], we
used the electrospinning technique. Electrospinning is the process with voltage to extrude
polymer solution into fine fibers for the production of micro/nano-fiber-covered stents
[20]. The electrospinning technique could support the covered membrane uniformly
adhered to the stent and easily regulate the thickness according to the clinical needs
[18,19]. Therefore, we selected the electrospinning to construct the backing layer on
316 L stainless stent and used the electrospraying process to regulate GEM and HP
on the covered membrane. To provide the flexibility of the membrane, polyurethane
(PU), with sufficient elastic property, was used as the material of drug-free backing
layer, which could effectively control majority of the inner drugs released to the
tissue-contacting side and additional supporting force for the main drug layer [18].
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were selected as two drug-storing layers to control the drug-releasing rate. In the
ratio of 1:4, PCL/PEG blends were used as the outer releasing layer with HP loaded,
while in the ratio of 9:1, PCL/PEG blends were used as the inner releasing layer with
GEM loaded (Figure 1). To our knowledge, this is the first study to show that the
biliary stent could be accompanied with PDT and chemotherapy for localized cholan-
giocarcinoma treatment.Methods
Materials
Polyurethane (PU), Polycaprolactone (PCL, Mw = 80,000), Polyethylene glycol (PEG,
Mw = 20,000), Tetrahydrofuran (THF), 1,1,1,3,3,3-Hexafluro-2-propanel (HFIP) and
Hematoporphyrin (HP) were purchased from Sigma-Aldrich (St Louis, MO). Gemci-
tabine (GEM) of clinical grade was supplied by National Taiwan University Hospital.
All other chemicals were of analytical grade and used as received.Preparation of PDT-chemo stent
The PDT-chemo stent, consisting of tri-layers of membranes, was made by electrospinning
and electrospraying dual-processes. The metallic stent was provided from the laboratory
of Dr. Fuh-Yu Chang in National Taiwan University of Science and Technology, and
the femtosecond laser was used to carve the 316 L stainless metallic tube. The unit of
electrospinning contained a high-voltage power supply, a motor to rotate the stent, a
syringe pump, and a 19G-needle that was connected by a tube to a syringe. The metallic
stent rotated by a motor was horizontally placed 15 cm away from the needle. The
solution of PU in HFIP (10 m/v%) was used for electrospinning process, while PCL/PEG
blends were mixed in HFIP/THF (1:1) solution for electrospraying process. Both PU andGEM
HP










Figure 1 Schematic illustration of the PDT-chemo stent as a biliary stent for cholangiocarcinoma
treatment. The covered membrane is composed of three layers with PU, PCL/PEG = 9:1 blends and PCL/
PEG = 1:4 blends. PU was employed as the material of the backing layer, and PCL/PEG blends were used in
drug-storing layers with GEM and HP loaded.
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backing layer of PU was first electrospun with voltage 14 kV, and was followed by the
drug-storing layer of PCL/PEG blends elecrosprayed with higher voltage 22 kV.
Herein, the drug-storing layer of PCL/PEG blends in molar ratio of 9:1 was loaded
with GEM covering the backing layer, followed by the HP coating on the top in PCL/
PEG molar ratio of 1:4 (Figure 1). The extruded polymer from the syringe of electr-
spinning/electrospraying was collected for only a short period time on cover glass for
optical microscopy (OM, Leica, Germany). Samples collected covered stent were prepared
by coating with thin gold film by sputtering PVD and visualized by scanning electron
microscopy (SEM, JSM-7000 F, Japan) operated at 15 KV.Drug electrosprayed efficiency
To further confirm the electrsprayed efficiency of loading drug in state of covered
membrane, the membrane was collected from the stent and absolutely dissolved in dimethyl
sulfoxide (DMSO) solution. After that, high-performance liquid chromatography (HPLC,
Waters e2695, USA) and ultraviolet–visible spectroscopy (UV/vis, JASCO V-550, USA)
were used to examine the extruded drugs of GEM and HP from the covered membrane
respectively.Drug release
The covered membrane was incubated in a sealed glass bottle with 0.5 ml phosphate-
buffered saline (PBS) as the releasing medium. The bottle was placed in a shaking incubator
at 37°C at a shaking speed of 50 rpm. At the predetermined time, 0.5 ml sample was
withdrawn and replaced with the same volume of fresh medium. Residual concentration
of drug in the membrane was counted by dissolving the membrane in DMSO solution as
the eluting medium. Samples were collected and analyzed under the UV–vis spectrometer
and HPLC. The morphology of membrane after 72 h of release was assessed by SEM
imaging. The values were presented as mean ± standard error (STD) in triplicate.
Statistical analysis was performed using the analysis student’s t-test. Values of p < 0.05
was considered being statistically significant.Results and discussion
Prototype of PDT-chemo stent
To make the stent with covered membrane more uniformly adhered to the surface
and easily regulate the thickness according to the clinical needs, electrospinning/
electrospraying has been regarded as the appropriate means for demonstrating the
PDT-chemo stent [18,19]. The covered stent can be manufactured by several elec-
trospinning methods: post-spinning modification, drug/polymer blends, emulsion
electrospinning and core-shell electrospinning [21]. Drug/polymer blends technique
could easily mix the drug with polymer directly and form a layer of membrane to
achieve sustained drug release. Therefore, in this study, the prototype of PDT-chemo stent
was constructed by drug/polymer blends technique via electrospinning and electrospray-
ing dual-processes. The backing layer was electrospun first from PU polymer solution,
followed by the electrospraying process from PCL/PEG blends solution with drug loaded.
Electrospinning is the process with voltage to extrude polymer solution into fine fibers for
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superior mechanical properties of the membrane and be introduced as the backing
layer for effectively controlling majority of the inner drugs released to the surrounding
tissue. During electrospinning, the organic solvent, which could be toxic to cells, will
be completely evaporated due to its high volatility [22]. Electrospraying has similar
preparation process to electrospinning but is usually used with higher voltage and
lower polymer density, which makes the polymer solution more easily broken up into
droplets [23,24]. The concept of electrospraying process was used to increase layer-to-
layer adhesion, which could avoid drug-storing layer cracking and separating from
backing layer during the stent expending.
The covered membrane is composed of three layers with PU, PCL/PEG = 9:1 blends
and PCL/PEG = 1:4 blends. PU was employed as the material of the backing layer, while
PCL/PEG blends were used in drug-storing layers with GEM and HP loaded (Figure 1).
Several materials (eg. Silicone, PTFE, and PU) have been approved by US Food and
Drug Administration (FDA) as the covered membrane on the stent [13]. Silicone was
reported to cause the acute inflammation to the surrounding tissue [25]. The PTFE,
however, could not be dissolved into any solvent [26]. Therefore, as the material of the
backing layer in this study, PU has been found able to be formed sufficiently thin and
flat on the metallic stent by electrospinning process and with elastic properties to allow
the covered stent to be homogeneously expanded [18]. Additionally, PU membrane has
been proved to prevent the tumor ingrowth effectively and to reduce the occlusion rate
of expandable metal stent in patients with malignant biliary obstruction [15]. The
distinct biodegradable properties of PCL and PEG blending were regarded as an
approach to controlling the drug-releasing rate in different blending ratio. The selection
of PCL is due to its good biocompatibility, drug permeability and relatively slow
degradation rate [27,28]. The hydrophilic PEG was selected to play a role in resulting in
regulating the drug-releasing rate, due to its easily acting on aqueous solution [14,29].
The prototype of PDT-chemo stent was imaged by photography and optical micros-
copy, which proved that the membrane was homogeneously covered on the stent surface
in each electrospun process (Figure 2). The optical microscopy (Figure 2b) revealed that
PU was formed in fine fibers with width around 5 to 10 μm; thus PCL/PEG blends
solution was favorable for generating submicron droplets (Figure 2c, d). The photograph
of membrane appeared brown (Figure 2d) due to the homogeneously dispersed of HP
coated on the top. Finally, the prototype of PDT-chemo stent could be easily removed
from the cylindrical collector without any surface damage (Figure 2e). The surface
morphology and cross section of the film was further investigated by SEM imaging
(Figure 3), which showed that the membrane was constructed of two sides with the
backing layer and drug-storing layer. The architecture of the backing layer was
constructed of fine fibers in networks structure, while drug-storing layer, attributed
to the droplets from electrospraying process was coated on the backing layer
roughly. The cross section of the membrane was smoothly with width in range from
170 to 190 μm. The thickness of the membrane could be optimized for the most
favorable thickness according to the clinical needs via regulating time during the
electrospun process.
To further confirm the electrosprayed amount of the drug on the covered membrane,












Figure 2 The photography and microscopic imaging of PDT-chemo stent. The prototype of PDT-
chemo stent in each step of electrospun/electrosprayed process is presented under the photography and
optical microscopic imaging. (a) 316 L stainless bare stent; (b) covered with PU backing layer; (c) covered
with inner drug-storing layer by PCL/PEG = 9:1 with GEM loaded; (d) covered with outer drug-storing layer
by PCL/PEG = 1:4 with HP loaded; (e) the prototype of PDT-chemo stent collected from cylindrical collector.
Optical microscopy shows the extruded polymer from the syringe of electrspinning/electrospraying processes.
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in PEG/PCL solution from 0.67 mg/ml to 6.67 mg/ml, the density of the HP from
the electrosprayed membrane increased gradually from 8.72 μg/cm2 to 63.59 μg/cm2 at
most, which was around 0.7 fold to the HP containing solution, as seemed to demonstrate
70% of electrosprayed efficiency (Figure 4a). By the same method, GEM had almost 100%
electrosprayed efficiency (Figure 4b) and had a tendency of increasing electrosprayed
efficiency by mixing with PCL/PEG blends due to its high hydrophilicity [30]. The
corresponding results of the concentration of the drug in the solution and the density
of the covered membrane could be an useful information to further imitate a clinical
dose regimen for cholangiocarcinoma treatment.
Carbon Conductive Tape
Backing layer Drug-storing layerCross section
Figure 3 SEM imaging of the covered membrane. The surface morphology and cross section of the
covered membrane from PDT-chemo stent was observed by SEM imaging, which showed that the
membrane was constructed of two sides with the backing layer and drug-storing layer.
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As illustrated in Figure 1, this PDT-chmo stent was designed to obtain a two-phased
drug release pattern, which is composed of a first burst-releasing phase and a later
slow-releasing phase with combination therapy for cholangiocarcinoma treatment.
Hydrophilic PEG was used as a regulator of drug release from PCL/PEG blends [31].
Figure 5 displays the drug releasing profiles from the covered membrane. At each
releasing time, the cumulative amounts of HP from PCL/PEG = 1:4 membrane, released
in the first hour (P < 0.01 relative to GEM), had a high initial burst 80% and reached
maximal cumulative release of nearly 98% within 24 h. Whereas, compared to HP in
the first hour, GEM within PCL/PEG = 9:1 membrane showed relatively slow drug
release in the first hour (50%). The significant difference of releasing kinetics between
HP and GEM was observed within 24 h, as indicated drug-releasing rate can be regu-
lated within 24 h by adjusting PEG and PCL compositions, then both drugs complete
releasing occurred during the time span between 24 h and 72 h. The mechanism of
drug release was reported by Liu et al. [32] and Lei et al. [14] that PEG acted as a pore
former in PCL/PEG blends, where the releasing rate from co-localization of protein/
drug and blends were proportional to PEG content. The hydrophilic PEG in PCL/PEG
blends easily acted on aqueous solution, which resulted in the formation of swollen
structure and subsequently increased the drug-releasing rate, as indicated the kinetics
of drug releasing was mainly due to the degradation of the PCL/PEG blends [14].
Although the slow releasing rate of GEM may not exclude the possibility of outer
drug-storing layer (PCL/PEG = 1:4) to delay parts of GEM release, we consider that
PCL/PEG = 1:4 membrane with high concentration of hydrophilic PEG polymer will
interact fast with aqueous solution, leading the membrane to degrade quickly within
the first few minutes [14]. Therefore, we suggest PCL and PEG with different molar
Figure 4 The electrosprayed amount of the drug on the covered membrane. The density of (a) HP and
(b) GEM coated on the covered membrane is illustrated on the vertical axis of this graph, while the drug
concentration of HP and GEM in PCL/PEG blends solution respectively is illustrated on the horizontal axis.
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releasing rate. In order to better meet the needs of clinical application, the thickness
of covered membrane and membrane composition could be further easily improved
according to our requirements by electrospinning/electrospraying technique [18,19].
After drug eluting in PBS solution, the surface morphology of the covered membrane
was investigated by SEM imaging (Figure 6). Generally, fine fiber architecture of the
backing layer was covered with roughness of the drug-storing layer (Figure 6a). After
72 h of drug eluting, rough surface of the drug-storing layer was converted to align-
ment (Figure 6b). This orderly structure indicates the degradation of PCL/PEG blends
from the surface, and only PU backing layer and partial PCL/PEG blends left on the
layer can be observed. The thickness of the cross section was reduced from around
Figure 5 The profile of drug release. Release of HP and GEM from covered membrane at each predetermined
time in PBS solution (mean ± STD, n = 3). Values of p < 0.01 is considered being statistically significant.
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drug release kinetics was mainly because of the degradation of PCL/PEG membrane,
not due to the diffusion or permeation of drugs through the membrane.
Herein, GEM is one of the first line chemo-drugs in the treatment of advanced chol-
angiocarcinoma, which is a prodrug belonging to an analog of deoxycytidine. Once
GEM is transported into the cell, it will be phosphorylated to an active form to inhibit
DNA synthesis [33]. Therefore, low initial burst of GEM may help to prevent undesired














After 72h incubation in PBS solution
Figure 6 SEM imaging of eluted covered membrane. After 72 h drug eluting in PBS solution, the surface
morphology (a, b) and cross section (c, d) of the covered membrane were observed by SEM imaging.
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when the stent is localized in bile duct. Overall, the prototype of PDT-chemo stent has
demonstrated the proof of concept of localized combination therapy for cholangiocarci-
noma. Based on the theory, the drug-releasing rate could be further regulated by changing
the initial electrospraying blend polymer solution, concentration, structure and type
of fibers and the amount of additives for the clinical needs [34,35].
Conclusions
In preliminary study, we have successfully developed a prototype of tri-layered covered
stent with PDTand chemotherapy. This PDT-chemo stent was prepared by electrospinning
and electrospraying dual-processes. The membrane is composed of PU backing layer as the
base and PCL/PEG drug-storing layers with GEM and HP on the top. The mixing of drugs
with different PCL and PEG composition demonstrated an effective strategy for regulating
the drugs release from the membrane. The release study has confirmed a two-phased drug
release pattern, which provides a proof of concept for the hypothesis that the PDT-chemo
stent is composed of a first burst-releasing phase from HP and a later slow-releasing phase
from GEM eluting. This two-phase of drug eluting stent may provide a new prospective of
localized controlled release treatment for cholangiocarcinoma disease.
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